🧬 Scientific summary on using CRISPR technology to improve immunotherapy for prostate cancer
Prostate cancer is one of the types of cancer that face major challenges in treatment through immunotherapy, as many of its tumors are classified as “immunologically cold” because of the limited presence of T cells within the cancerous tissue. In a recent study, researchers used an innovative technique based on CRISPR to target RNA inside prostate cancer cells, with the aim of reactivating and activating the immune response within the tumor. The results showed a notable improvement in tumor tolerance to immunotherapy, which may open new horizons for treatment.
🧠 Why is prostate cancer difficult to treat with immunotherapy?
Prostate tumors are usually known as “immunologically cold” tumors, which means that the number of immune T cells entering them is very small. The lack of sufficient immune cells in the tumor makes it difficult for the body to target and destroy cancer cells using immunotherapy.
Part of this weakness is due to the deficiency of the MHC-1 complex, which acts as a molecular signal that leads T cells to recognize cancer cells. Without this complex, malignant cells become almost invisible to the immune system, and thus immunotherapy fails.
An important scientific point
🩺 The molecular mechanism responsible for the loss of the MHC-1 complex
- There is a specific protein called SPSB1, responsible for destroying the MHC-1 complex.
- In prostate cancer cells, SPSB1 is produced in high amounts because its mRNA is abnormally shortened.
- Shortening in the mRNA means producing a large amount of SPSB1 protein, which leads to the destruction of greater numbers of the MHC-1 complex.
- As a result, the presence of the complex on the cell surface decreases, which blocks the signal that attracts immune cells.
This mechanism is considered one of the reasons for prostate cancer’s resistance to immunotherapy, as the shortening of mRNA gives cancer cells an exceptional advantage in secreting proteins that weaken the immune response.
🧪 CRISPR technology restores the immune “magnet” to tumors
A research team led by the Duke University School of Medicine used a CRISPR Cas13 system directed toward RNA to modify the mRNA responsible for producing the SPSB1 protein in prostate cancer cells. This technology does not cut the RNA as in conventional CRISPR uses, but instead binds to a specific part of the mRNA molecule to reduce the shortening process, thereby restoring the length of the mRNA to its normal state.
The main scientific result of this modification is:
- A decrease in the production of SPSB1 protein inside cancer cells.
- The return of the level of the MHC-1 complex to an increase.
- An increase in the attraction of immune T cells to tumors, which enhances the body’s response against cancer.
In this way, tumors become more sensitive to the corresponding immunotherapy known as immune checkpoint therapy.
What did the research reveal?
🌱 How does this discovery make a difference in cancer treatment?
Researchers believe that this approach represents a qualitative leap in the treatment of “immunologically cold” tumors, as the effectiveness of immunotherapy can be enhanced and result in:
- Reducing the need for toxic drugs that harm healthy cells.
- Opening horizons for using this type of experimental treatment alongside traditional treatments.
- Expanding treatment possibilities to include other types of cancers resistant to immunotherapy.
Eric J. Wagner, PhD also pointed out that cancer may develop resistance to treatments, but it is not capable of overcoming the enhanced immune response with a compatible set of targeted drugs.
Health takeaway
🧬 Future applications in other types of cancers
After the success of these experiments in treating prostate cancer in animal models, the research team plans to expand the trials to include other cancers known for being “immunologically cold,” such as pancreatic cancer.
The project received initial funding from prestigious national institutes to study the ability of this technology to improve therapeutic outcomes in other cancer types, in an important step toward effective and comprehensive treatment.
🧠 How does CRISPR Cas13 work in modifying RNA?
The CRISPR Cas13 system represents an advancement in gene-editing techniques, as it targets RNA molecules instead of DNA, allowing molecular markers that regulate protein production to be modified directly.
In this study, CRISPR was prepared to act like a molecular gun that attaches to the end of the relevant mRNA instead of cutting it, preventing the modification processes that make the mRNA shorter and lead to the production of proteins that enhance tumor resistance to treatment.
This method gives scientists a precise tool that enables them to control gene expression without causing deep genetic damage, and opens new areas for treatments that rely on temporary modifications in proteins inside cells.
An important scientific point
🩺 Conclusion: a promising future for treating prostate cancer
This research combines a deeper understanding of the nature of cancer diseases and modern molecular techniques to provide a potential treatment that could transform how prostate cancer is confronted.
By enhancing the immune system’s ability to recognize and attack the tumor, CRISPR technology opens the door to safer and more effective therapies. Researchers also point to the possibility of expanding the use of this method to other types of cancers that lack a natural immune response.
The modern treatment was distinguished by the absence of clear unwanted side effects, which is a promising indication of the possibility of developing drugs that target modified molecules in cells without major risks to the body.
This innovation remains a landmark in the development of immunotherapies and confirms the importance of continued research in biochemistry and RNA biology to develop new solutions in the field of cancer treatment.
📚 Related articles
Discover more from Mohdbali
Subscribe to get the latest posts sent to your email.
